Venezuela - španělština - Instituto Nacional de Higiene

pharmaceutical group pg, c.a. - azacitidina - polvo liofilizado para suspension - 100 mg

Venezuela - španělština - Instituto Nacional de Higiene

representaciones benares c.a. - azacitidina - polvo - 100 mg

Ekvádor - španělština - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

hetero labs limited india - cada vial contiene: azacitidina 100.000mg - polvo liofilizado para inyeccion - cada vial contiene: azacitidina 100.0mg

Evropská unie - španělština - EMA (European Medicines Agency)

celgene europe bv - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Evropská unie - španělština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

advance scientific del peru s.a.c. - droguerÍa - polvo para suspension inyectable - por vial - - azacitidina

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biotoscana farma de peru s.a.c. - azacitidina; - polvo para solucion inyectable - por vial - azacitidina

Venezuela - španělština - Instituto Nacional de Higiene

laboratorios nolver, c.a. - azacitidina - polvo liofilizado para suspen. inyectabl - 100 mg

Evropská unie - španělština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, aguda - agentes antineoplásicos - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).